ArticleAging2019
Immune senescence and immune activation in elderly colorectal cancer patients.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- Bridging aging and colorectal cancer: synergistic roles of inflammaging and immunosenescence.Frontiers in immunology · 2026Review
- Global research trends of immunosenescence and immunotherapy: A bibliometric study.Human vaccines & immunotherapeutics · 2025Review
- Review
- Prognostic value of CD28⁻CD57⁺CD8⁺ T cells for early immunotherapy response in hepatocellular carcinoma: a prospective observational study.Scientific reports · 2025Observational
- AI-driven chemotoxicity prediction in colorectal cancer: impact of race, SDOH, and biological aging.BMC cancer · 2025Article
- Pathogenic SIV infection is associated with acceleration of epigenetic age in rhesus macaques.The Journal of clinical investigation · 2025Article
- Risk of recurrence in early-onset versus late-onset non-metastatic colorectal cancer, 2004-2019: a nationwide cohort study.The Lancet regional health. Europe · 2024Article
- Senescence-based colorectal cancer subtyping reveals distinct molecular characteristics and therapeutic strategies.MedComm · 2023Article
- Cellular Senescence, Inflammation, and Cancer in the Gastrointestinal Tract.International journal of molecular sciences · 2023Review
- The sCD14-ST predictive value in the development of adverse outcomes in operated colorectal cancer patients (diagnostic study).Annals of medicine and surgery (2012) · 2023Article
- Presepsin (soluble CD14 subtype) as a risk factor for the development of infectious and inflammatory complications in operated colorectal cancer patients.Annals of coloproctology · 2022Article
- Upregulation of p16INK4A in Peripheral White Blood Cells as a Novel Screening Marker for Colorectal Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Age-related Differences in Tumour Characteristics and Prognostic Factors for Disease Progression in Cutaneous Squamous Cell Carcinoma of the Head and Neck.Acta dermato-venereologica · 2022Article
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.International urology and nephrology · 2022Article
- Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients.Frontiers in oncology · 2022Article
- Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps.Turkish journal of biology = Turk biyoloji dergisi · 2022Article
- Review
- The overexpression of Tipe2 in CRC cells suppresses survival while endogenous Tipe2 accelerates AOM/DSS induced-tumor initiation.Cell death & disease · 2021Article
- Aging- and Tumor-Mediated Increase in CD8ImmunoHorizons · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our previous study, we found that low thymic output and short telomere length were associated with a higher risk of tumor in elderly cancer patients. Here, we aimed to examine in depth the impact of immunological and biological senescence and immune activation on disease outcome in elderly patients with colorectal cancer (CRC).Peripheral blood samples from 81 CRC patients were studied for immune activation, immune senescence and recent thymic emigrant(RTE) CD4 and CD8 cells by flow cytometry. T-cell receptor rearrangement excision circle (TREC) levels and telomere lengths were measured by real-time PCR. Plasma levels of microbial translocation markers, LPS and sCD14, were quantified by ELISA. While TREC levels and telomere length were not prognostic of disease outcome, high percentages of immune senescent and immune activated CD8 cells were associated with a higher risk of a negative event (relapse, progression, or death) in all studied patients and disease relapse in I-III staged patients. Levels of sCD14 and LPS were higher in patients who will experience a negative event than in patients who will not. In conclusion, in elderly CRC patients higher immunological senescence and immune activation negatively impact the disease outcome; how these characteristics influence the antineoplastic treatments remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.